Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Hcy causes oxidative stress, reducing blood flow to the eyes and damaging eye cells, leading to inflammation, nerve damage, and faster cell death
Orforglipron Phase 3 data demonstrates that a non-peptide oral molecule can achieve weight loss comparable to injectable semaglutide, potentially expanding patient access by removing injection barriers
Current FDA labeling for semaglutide products includes warnings or precautions involving: Acute pancreatitis Acute gallbladder disease Acute kidney injury due to volume depletion Severe gastrointestinal reactions Hypoglycemia when combined with insulin or insulin secretagogues Diabetic retinopathy complications in susceptible patients Serious hypersensitivity reactions Pulmonary aspiration risk during general anesthesia or deep sedation Semaglutide labeling also contains a boxed warning regarding thyroid C-cell tumors observed in rodents
Secondly, the ROS attack accelerates apoptosis of retinal tissues and cells and aggravates DR, 68 with the activated polyol pathway, hexosamine pathway, and PKC pathway, as well as advanced glycation end products (AGEs) accumulation involved in the process
Many patients also find that achieving a healthier weight can reduce their need for other medications related to cholesterol or blood sugar management
The practical significance of this selectivity is considerable
